Zhen et al. (117) discovered that the Qiliqiangxin capsule can effectively improve the clinical symptoms of patients with HF, reduce the serum levels of MMP-2, MMP-9, and MMP-13, increase the levels of tissue inhibitor of matrix metalloproteinases (TIMP)-1 and TIMP-2, regulate the expression of MMPs and TIMPs in patients with HF, and improve the metabolic disorders of the extracellular matrix, thereby inhibiting myocardial fibrosis and ventricular remodeling and improving cardiac function. Here, MMP13 is linked to hydrops fetalis.